

International Activities (National Center for Zoonotic, Vector-Borne, and Enteric Diseases).

Strategic Planning and Linking to CDC Goals (National Center for Zoonotic, Vector-Borne, and Enteric Diseases).

2. *Updates on Surveillance Systems:* Biosurveillance.

3. Strategic Directions for CCID.

4. Budget Updates.

Written comments are welcome and should be received by the contact person listed below prior to the opening of the meeting.

*Contact Person for More Information:*

Harriette Lynch, Office of the Director, CCID, CDC, Mailstop A-45, 1600 Clifton Road, NE., Atlanta, Georgia 30333, Telephone (404) 639-4035.

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: April 9, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-8336 Filed 4-16-08; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### **Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Type-2 Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus, Potential Extramural Project (PEP) 2008-R-04.**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the aforementioned meeting.

*Time and Date:* 1 p.m.-4 p.m., May 30, 2008 (Closed).

*Place:* Teleconference.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in section 552b(c)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

*Matters To Be Discussed:* The meeting will include the review, discussion, and evaluation of "Type-2 Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus, PEP 2008-R-04."

*Contact Person for More Information:*

Linda Shelton, Program Specialist, Coordinating Center for Health and Information Service, Office of the Director, CDC, 1600 Clifton Road, NE., Mailstop E21,

Atlanta, GA 30333, Telephone (404) 498-1194.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: April 9, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-8326 Filed 4-16-08; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

[Docket Number 128]

#### **Notice of Draft Document Available for Public Comment**

**AGENCY:** National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice of Draft Document Available for Public Comment.

**SUMMARY:** The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the availability of the following draft document available for public comment entitled "Preventing Occupational Exposures to Lead and Noise at Indoor Firing Ranges." The draft document and instructions for submitting comments can be found at <http://www.cdc.gov/niosh/review/public/-128/>. Comments should be provided to the NIOSH Docket Number above.

*Public Comment Period:* April 17, 2008 through June 30, 2008.

*Status:* Written comments may be submitted to the NIOSH Docket Office, Robert A. Taft Laboratories, 4676 Columbia Parkway, Mailstop C-34, Cincinnati, Ohio 45226. All material submitted to the Agency should reference NIOSH Docket number 128 and must be submitted by June 30, 2008, to be considered by the Agency. All electronic comments should be formatted as Microsoft Word.

All information received in response to this notice will be available for public examination and copying at the NIOSH Docket Office, Room 111, 4676 Columbia Parkway, Cincinnati, Ohio

45226. After the comment period has closed, comments may be accessed electronically at <http://www.cdc.gov/NIOSH> under the link to the NIOSH docket. As appropriate, NIOSH will post comments with the commenters' names, affiliations, and other information, on the Internet.

*Background:* This Alert is intended to address the concerns of Federal, State, and local law enforcement agencies about occupational exposures of their officers to lead and noise during firearms training and qualifications. The Alert describes the health effects that can occur from occupational exposures to lead and noise at indoor firing ranges and recommends steps that firing range operators, employers, and workers should take to minimize the health risk to workers and shooters.

This guidance document does not have the force and effect of law.

*Contact Person for Technical Information:*

Chucri (Chuck) A. Kardous, Commander, U.S. Public Health Service, Senior Research Engineer, Division of Applied Research and Technology, CDC/NIOSH, 4676 Columbia Parkway, C27, Cincinnati, Ohio 45225, Phone: 513-533-8146, E-mail: [ckardous@cdc.gov](mailto:ckardous@cdc.gov).

*Reference:* Web address for this document: <http://www.cdc.gov/niosh/review/public/128/>.

**James D. Seligman,**

*Chief Information Officer, Centers for Disease Control and Prevention.*

[FR Doc. E8-8259 Filed 4-16-08; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### **Proposed Collection; Comment Request; Reinstatement of Generic Clearance for Partners and Customers Satisfaction Surveys**

*Summary:* In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Center for Scientific Review (CSR), the National Institutes of Health (NIH) will publish periodic summaries of proposed projects. To request more information or to obtain a copy of the information collection plans, call the CSR Director of Planning, Analysis, and Evaluation on 301-435-1133.

*Proposed Collection: Title:* Reinstatement of Generic Clearance for Voluntary Partners and Customers

Satisfaction Surveys: *Reinstatement:* The information collected in these surveys will be used by the Center for Scientific Review management and personnel: (1) To assess the quality of the modified operations and processes now used by CSR to review grant applications; (2) To assess the quality of service provided by CSR to our customers; (3) To enable identification of the most promising biomedical research that will have the greatest impact on improving public health by using a peer review process that is fair,

unbiased from outside influence, timely, and (4) To develop new modes of operation based on customer need and customer feedback about the efficacy of implemented modifications. These surveys, which will be both quantitative and qualitative, are designed to assess the quality of services we provide to our major external customers. Customers include the research scientists who submit applications for grant funding to NIH. Those grant applications are reviewed and ranked by the grant scientific peer review study groups'

members and chairs. These surveys will almost certainly lead to quality improvement activities that will enhance and/or streamline CSR's operations. Our partners include current grant scientific peer review study groups' members and chairs.

*Frequency of Response:* On occasion.  
*Affected Public:* Scientific peer review study groups' members and chairs, grant applicants, other members of the research community.

*Type of Respondents:* Adult scientific professionals.

ESTIMATES OF ANNUALIZED HOUR BURDEN

Instrument/activity	Annual number of respondents	Number of responses per respondent	Annual average burden per response (hours)	Total burden hours per annual collection
Focus Groups .....	75	1	2.5	187.5
Mail/telephone/e-mail Surveys .....	5,000	1	0.25	1,250
Annual Total .....	5,075			1,437.5

*Request For Comments:* Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Whether the proposed collection of information is necessary for the proper performance of the function of the agency, including whether the information will have practical utility; (2) The accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) Ways to enhance the quality, utility, and clarity of the information to be collected; and (4) Ways to minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

*For Further Information Contact:* To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Andrea Kopstein, Director of Planning, Analysis, and Evaluation, Center for Scientific Review, NIH, Room 3030, 6701 Rockledge Drive, Bethesda, MD 20892-7776, or call non-toll-free number (301) 435-1133 or E-mail your request, including your address to: [kopsteina@csr.nih.gov](mailto:kopsteina@csr.nih.gov).

*Comments Due Date:* Comments regarding this information collection are best assured of having their full effect if received within 60 days of the date of this publication.

Dated: April 7, 2008.

**Andrea Kopstein,**

*Director of Planning, Analysis, and Evaluation.*

[FR Doc. E8-8230 Filed 4-16-08; 8:45 am]

**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, Public Health Service, HHS.

**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will

be required to receive copies of the patent applications.

**Engineered Human Antibody Constant Domains (Nanoantibodies) as Scaffolds for Binders**

*Description of Technology:* The invention describes conceptually novel scaffolds based on engineered human antibody constant domains (nanoantibody scaffold). They are highly soluble, very stable, monomeric, and can be expressed at high levels. Furthermore, large libraries are generated from which binders to antigens are selected and characterized.

*Advantages:*

The engineered antibody domains are more stable compared to existing domain antibodies.

The nanoantibodies are derived from human sequences and are likely to have minimal toxic and immunogenic effects.

The small size of the nanoantibodies ensures efficient penetration in tissues including solid tumors and lymphoid tissues where HIV replicates, and also efficient neutralization of viruses, e.g. HIV, that have evolved to avoid neutralization by naturally occurring large size IgGs generated by the immune system.

*Applications:* The nanoantibodies have potential for diagnosis and treatment of cancer and AIDS as well as diseases of the immune systems and other diseases.

*Development Status:* Proof of concept experiments have been completed.

*Inventor:* Dimiter Dimitrov (NCI).

*Patent Status:* U.S. Provisional Application No. 61/063,245 filed 31 Jan